You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

22 search results for: airway remodeling

<b>Airway</b> <b>Remodeling</b> in Type 2 Asthma is Driven by IL-4 and IL-13

expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min

Pulmonology

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of <b>Airway</b> <b>Remodeling</b>?

expert video

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

30 min

Pulmonology

Professor Klaus Rabe shares a patient case highlighting the burden of disease associated with airway remodeling and discusses practical aspects of identifying and managing airway remodeling in severe asthma patients with Professor Porsbjerg and Dr Castro.

ERS 2024 | Can Biologics Affect <b>Airway</b> <b>Remodeling</b>?

expert video

ERS 2024 | Can Biologics Affect Airway Remodeling?

20 min

Pulmonology

Dr Mario Castro presents the latest clinical data on biologics showcasing their effect on airway remodeling parameters and airway hyperresponsiveness in patients with severe asthma.

expert video

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

78 min

Pulmonology

Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss the pathophysiology of airway remodeling and its impact on patients with severe asthma.

ADVENT On Air | Diving Deep: Exploring the Impact of <b>Airway</b> <b>Remodeling</b> in Severe Asthma

Podcast

ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

20 min

Pulmonology

Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma.

Type 2 Inflammation and <b>Airway</b> <b>Remodeling</b> Drive Lung Function Decline

videoanimation

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

4 min

Pulmonology

Explore the impact of type 2 inflammation and airway remodeling on lung function decline in asthma.

ERS 2024 | Pathophysiologic Mechanisms of <b>Airway</b> <b>Remodeling</b> in Severe Asthma

expert video

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

15 min

Pulmonology

Professor Celeste Porsbjerg presents the pathophysiology and disease processes involved in airway remodeling in severe asthma.

Clinical Manifestations Associated With <b>Airway</b> <b>Remodeling</b> in Asthma

expert video

Clinical Manifestations Associated With Airway Remodeling in Asthma

2 min

Type 2 Inflammation

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

expert video

Role of Type 2 Cytokines in Asthma and COPD

2 min

Type 2 Inflammation

Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.

Mucus Plugging Is a Key Component of <b>Remodeling</b> in Asthma, Leading to Fixed <b>Airway</b> Obstruction

Infographic

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

3 min

Pulmonology

Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma

interactivity

Pathways to Disease: Inflammation in COPD

5 min

Pulmonology

Learn about the pathophysiology of COPD and the involvement of chronic inflammation on the airways

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease <b>Remodeling</b>

expert video

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

15 min

Pulmonology

Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region